Recent Updates
Recently added Catalysts
PDUFA Calendar 2026
November 2026
+2 More
+1 More
+1 More
+2 More
Cogent Biosciences, Inc.
bezuclastinib combination
Bezuclastinib, a selective KIT inhibitor developed by Cogent Biosciences, is currently under regulatory review for the treatment of gastrointestinal stromal tumors (GIST) in patients who have previously received imatinib and are resistant or intolerant to it. The FDA has accepted the New Drug Application (NDA) for bezuclastinib, granting it Priority Review status with a Prescription Drug User Fee Act (PDUFA) action date set for November 30, 2026. This marks a significant milestone as the program transitions from active development to regulatory evaluation. The pivotal evidence supporting bezuclastinib's efficacy stems from the phase 3 PEAK trial (NCT05208047), which is a global, randomized study comparing the combination of bezuclastinib plus sunitinib to sunitinib monotherapy in patients with imatinib-resistant or intolerant GIST. Although the trial's full sample size and detailed endpoint hierarchy have not been disclosed, the efficacy results are compelling. At the cutoff date of September 30, 2025, the combination therapy demonstrated a 50% reduction in the risk of progression or death compared to sunitinib alone, with a hazard ratio of 0.50 (95% CI 0.39–0.65). Additionally, the median progression-free survival (PFS) improved significantly from 9.2 months to 16.5 months. The overall response rate (ORR) was reported at 46% for the combination therapy compared to 26% for sunitinib monotherapy, with a highly significant p-value of less than 0.0001. However, overall survival data remains immature, suggesting that the approval case will largely rely on PFS and ORR rather than overall survival metrics. The market analysis indicates a global market size for second-line GIST after imatinib estimated at $1-2 billion. There is a clear unmet need in this space, as the current standard of care, sunitinib, has limited progression-free survival and response rates, with no approved therapies having displaced it for nearly two decades. Bezuclastinib is classified as best-in-class, representing a next-generation KIT-directed therapy that aims to enhance treatment outcomes on an established targeted backbone. Despite the promising data, several key risks must be considered. The approval is primarily based on a single positive phase 3 study, which may raise concerns regarding the robustness of the evidence, particularly in terms of overall survival. Regulators may also scrutinize whether the benefits of bezuclastinib over sunitinib are sufficiently durable and clinically meaningful to justify its use in a chronic oncology setting. Additionally, while no new safety signals have been reported, the combination therapy may inherit the toxicity profile of sunitinib, and any emerging tolerability concerns could lead to labeling restrictions during the FDA review process. The upcoming catalysts include the FDA's PDUFA action date and the potential for an advisory committee meeting, although the timing for the latter has not been disclosed. Given the favorable competitive landscape, characterized by a static market dominated by sunitinib and a significant unmet need for more effective treatment options, the estimated probability of approval (PoA) for bezuclastinib stands at 82.5%. The primary reason it is not considered near-certain is the absence of mature overall survival data, which the FDA may weigh against the benefits observed in the trial. Overall, the program's strong efficacy data, priority review status, and lack of immediate safety concerns position bezuclastinib favorably in the regulatory landscape.... Show more
Gastrointestinal Stromal Tumors (GIST) in patients who previously received imatinib
Drug: bezuclastinib combination. Indication: Gastrointestinal Stromal Tumors (GIST) in patients who previously received imatinib. Timeline: November 30, 2026. FDA accepted an NDA and granted Priority Review for the bezuclastinib combination in GIST patients previously treated with imatinib; PDUFA target action date is November 30, 2026.... Show more
BridgeBio Pharma, Inc.
BBP-418 (oral)
BBP-418, an oral substrate supplementation therapy developed by BridgeBio Pharma (Nasdaq: BBIO), demonstrates a high Probability of Approval (PoA) of 78.5% for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). This optimistic outlook is supported by positive top-line results from Phase 3 trials, the FDA's designation of Priority Review, and the absence of any approved competing therapies for this condition [2][3][5]. The regulatory designations for BBP-418 in the context of LGMD2I/R9 include Fast Track and Orphan Drug designations, while it has not received Breakthrough Therapy designation or Accelerated Approval. The Priority Review status further emphasizes the urgency and significance of this therapy in addressing a critical unmet medical need. Market analysis indicates that the global market size for LGMD2I/R9 is estimated at approximately $120 million, reflecting a small yet severely affected patient population. The unmet need is substantial, as there are currently no approved disease-modifying therapies available for LGMD2I/R9, leaving patients without options to stabilize muscle function or improve glycosylation of α-dystroglycan (αDG) [2][5]. BBP-418 is classified as a first-in-class therapy, targeting the FKRP enzyme pathway, which is crucial for the disease's molecular mechanism. BBP-418 is currently in the PDUFA (Priority Review) phase, following the FDA's acceptance of its New Drug Application (NDA) on May 27, 2026. The target action date for the FDA's decision is set for November 27, 2026 [2][5]. The pivotal Phase 3 trial, known as FORTIFY (NCT05775848), is a multinational, double-blind, randomized, placebo-controlled study that enrolled approximately 81 individuals aged 12 to 60 years. Participants were randomized in a 2:1 ratio to receive either BBP-418 or a placebo. The primary endpoint of the study is the change in the Non-Ambulatory and Ambulatory Scale (NSAD) score from baseline at 36 months, with a secondary focus on glycosylated αDG levels at 12 months [1][8]. BridgeBio has reported promising top-line results from the FORTIFY trial, showing a statistically significant 1.8-fold increase in glycosylated αDG levels in the BBP-418 group compared to the placebo group at the 12-month mark (from 22.7% to 39.6% of control) [3]. Clinically, patients exhibited statistically significant improvements across all key endpoints, including ambulation and motor performance. Safety data indicated that BBP-418 was well-tolerated, with no new or unexpected adverse events reported [3]. The regulatory designations for LGMD2I/R9 highlight the serious unmet need that BBP-418 aims to address. While the drug has not received Breakthrough Therapy designation, this may reflect the FDA's cautious approach regarding surrogate endpoints, despite the compelling biomarker data [3]. In terms of competitive landscape, BBP-418's potential approval could draw parallels with the recent approval of Eteplirsen for Duchenne muscular dystrophy, which faced scrutiny over surrogate endpoints but was ultimately approved due to clear biomarker benefits and the absence of alternatives. Conversely, Golodirsen encountered delays due to insufficient clinical correlation. BBP-418's robust biomarker response and clinical improvements position it favorably in this context [3]. The justification for the 78.5% PoA stems from the encouraging Phase 3 data, the FDA's Priority Review designation, and the first-in-class status in a market devoid of effective therapies. However, key risks remain, including the potential for safety signals in long-term exposure and regulatory scrutiny regarding the surrogate endpoint. The upcoming PDUFA decision on November 27, 2026, represents a critical catalyst for approval and market entry [2][5]. If approved, BBP-418 may also qualify for a Priority Review Voucher due to its Rare Pediatric Disease designation, enhancing the value proposition for BridgeBio's portfolio [3].... Show more
limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)
Drug: BBP-418 (oral). Indication: limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Timeline: 2026-11-27. FDA accepted BridgeBio's NDA for oral BBP-418 for individuals with LGMD2I/R9, granted Priority Review, assigned a PDUFA target action date of November 27, 2026, and indicated it is not currently planning an advisory committee meeting.... Show more
Savara, Inc.
molgramostim
Molgramostim, administered via inhaled nebulizer, has shown statistically significant and clinically meaningful improvements in pulmonary gas transfer among patients with autoimmune pulmonary alveolar proteinosis (autoimmune PAP) in the pivotal Phase 3 IMPALA-2 trial. This promising outcome supports a high Probability of Approval (PoA) of 85.0% for the upcoming FDA decision. In terms of regulatory designations for autoimmune PAP, molgramostim has received the following classifications: { "FastTrackDesignation": false, "OrphanDrugDesignation": true, "BreakthroughTherapyDesignation": true, "PriorityReview": true, "AcceleratedApproval": false } The market analysis indicates a global market size of approximately $120 million for autoimmune PAP. There is a significant unmet need, as autoimmune PAP is a rare, chronic lung disease with no approved pharmacologic therapies. Current management relies on invasive whole-lung lavage procedures, highlighting the urgent requirement for non-invasive treatment options. Molgramostim is classified as a first-in-class therapy. The estimated Probability of Approval stands at 85.0%. However, several key risks must be considered. First, while the trial reported no notable safety concerns, the long-term safety profile of chronic GM-CSF inhalation in this rare population remains to be fully established post-approval. Second, the lack of statistical significance in the SGRQ-A (quality of life) score at 24 weeks may lead to increased scrutiny from the FDA regarding the consistency of clinical benefits across all endpoints. Additionally, the ongoing open-label pediatric trial (NCT06431776) may present challenges, as the absence of robust pediatric efficacy data could limit the initial labeling scope or necessitate post-marketing commitments. Upcoming catalysts include the FDA approval decision, with the PDUFA date set but not publicly disclosed, and the publication of long-term open-label data covering a 96-week period, with timing also not disclosed. Savara Pharmaceuticals (SVRA) is advancing molgramostim as a first-in-class inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune PAP. This rare, chronic lung disease is characterized by the accumulation of surfactant protein in the alveoli, leading to severe respiratory impairment. Currently, there are no approved pharmacologic therapies, and management relies on invasive procedures that do not address the underlying pathophysiology. The global market for autoimmune PAP is estimated at approximately $120 million, driven by a small but critically underserved patient population with a profound unmet medical need. Molgramostim works by restoring GM-CSF activity in the lungs, thereby enhancing macrophage function to clear surfactant. The pivotal Phase 3 IMPALA-2 trial (NCT04544293) was a global, randomized, double-blind, placebo-controlled study involving 160 adult patients. The primary endpoint was the change in diffusing capacity of the lung for carbon monoxide (DLCO) from baseline to week 24. Results demonstrated a least-squares mean change of 9.8 percentage points for molgramostim compared to 3.8 for placebo, with an estimated treatment difference of 6.0 percentage points (95% CI, 2.5 to 9.4; P<0.001). At week 48, the improvement persisted (11.6% vs. 4.7%). Exploratory endpoints also indicated reduced surfactant burden via ground glass opacity (GGO) scores and improved exercise capacity. The safety profile was favorable, with 98% of molgramostim patients completing the 48-week period and adverse event rates similar to placebo, with no notable safety concerns. Regulatory support for molgramostim is robust. The FDA granted Breakthrough Therapy Designation and Orphan Drug Designation specifically for autoimmune PAP in late 2024. The program is also eligible for Priority Review upon NDA submission, reflecting the drug’s potential to address a rare condition with no alternatives. Molgramostim is classified as first-in-class, as no other approved drug shares its GM-CSF inhalation mechanism for PAP. Comparable precedents include the approval of other first-in-class therapies for rare lung diseases, where robust physiological endpoints like DLCO were sufficient for approval despite limited quality-of-life significance in early phases. The FDA has historically accepted such data for rare diseases with high unmet need. The Probability of Approval is estimated at 85.0%, justified by the statistically significant primary endpoint, favorable safety profile, strong regulatory designations, and the critical unmet need in a rare disease with no alternatives. Key risks include potential long-term safety uncertainties and the lack of pediatric efficacy data, which may necessitate post-marketing studies. The primary catalyst is the FDA approval decision, with the PDUFA date set but not publicly disclosed. Savara’s track record includes successful development of rare disease therapies, further supporting confidence in this program’s regulatory success. This approval would represent a landmark therapeutic advance for patients suffering from autoimmune PAP.... Show more
autoimmune pulmonary alveolar proteinosis (autoimmune PAP)
Drug: molgramostim. Indication: autoimmune pulmonary alveolar proteinosis (autoimmune PAP). Timeline: 2026-11-22. The FDA extended review of Savara’s molgramostim BLA under Priority Review by three months; the new PDUFA target action date for approval in autoimmune PAP is November 22, 2026.
Sanofi
venglustat
Venglustat (GZ402671), developed by Sanofi (ticker: SNY), is an investigational oral small-molecule glucosylceramide synthase (GCS) inhibitor designed to address the neurologic manifestations of type 3 Gaucher disease (GD3). This rare, progressive lysosomal storage disorder is characterized by visceral symptoms and chronic neurologic deficits, including ataxia, dystonia, and gaze palsy. Currently, enzyme replacement therapy (ERT), such as imiglucerase (Cerezyme), is the only approved treatment but fails to penetrate the blood-brain barrier, leaving a significant gap in addressing the central nervous system (CNS) pathology associated with GD3. Venglustat represents a first-in-class mechanism, as it is the only GCS inhibitor specifically targeting GD3, thereby offering a novel therapeutic approach to a pressing unmet medical need. The global market for GD3 is estimated at $120 million, a figure that reflects the disease’s rarity, with a prevalence of approximately 1 in 500,000 to 1 million. Despite this limited market size, the unmet medical need is substantial, as there are currently no approved therapies that effectively target the neurologic aspects of GD3. The ongoing LEAP2MONO trial (NCT05222906) is a Phase 3, double-blind, active-comparator, superiority study that evaluates the efficacy of venglustat against imiglucerase in patients aged 12 and older with GD3. This study involves 43 participants across two treatment arms, with co-primary endpoints focusing on changes in the Scale for Assessment and Rating of Ataxia (SARA) modified total score and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Secondary endpoints include assessments of spleen and liver volume, platelet count, hemoglobin levels, and depression scores. In mid-2024, Sanofi announced that venglustat successfully met its primary endpoint and achieved three of four key secondary endpoints, paving the way for global regulatory filings. The drug has been granted Fast Track and Orphan Drug designations in the U.S., EU, and Japan for GD3, with Priority Review anticipated for the New Drug Application (NDA). Comparative precedents include miglustat, a GCS inhibitor for Niemann-Pick C that failed due to inadequate CNS efficacy, and eliprolimab, a lysosomal modulator for GD1 that received Accelerated Approval based on surrogate endpoints. Venglustat’s success in achieving primary neurologic endpoints in a well-defined cohort positions it favorably in relation to eliprolimab's approval pathway. The estimated Probability of Approval (PoA) for venglustat stands at 78.5%, reflecting robust efficacy data, strong regulatory designations, and a clear unmet need. However, key risks must be considered, including variability in SARA scoring, safety concerns in the pediatric population, and potential regulatory scrutiny regarding the need for additional evidence from the FDA. Upcoming catalysts, such as the PDUFA decision and the publication of Phase 3 results, are critical for investors. For those invested in Sanofi, venglustat presents a high-value, first-in-class opportunity within a niche but critically underserved rare disease market, with the potential for global exclusivity and premium pricing.... Show more
type 3 Gaucher disease (GD3)
Drug: venglustat. Indication: type 3 Gaucher disease (GD3). Timeline: 2026-11-25. FDA granted priority review to the NDA for venglustat for the treatment of type 3 Gaucher disease (GD3); the target action date for the FDA decision is November 25, 2026.
GSK plc
neladalkib (NVL-655)
Neladalkib (NVL-655) is an innovative, brain-penetrant, ALK-selective tyrosine kinase inhibitor under development by Nuvalent for the treatment of ALK-positive non-small cell lung cancer (NSCLC), specifically targeting patients who have previously been treated with ALK TKIs. The drug is currently in regulatory review, with the FDA having accepted the New Drug Application (NDA), granted Priority Review status, and established a Prescription Drug User Fee Act (PDUFA) date of November 27, 2026. The supporting clinical data stems from the global ALKOVE-1 Phase 1/2 study (NCT05384626), which is designed as a dose-escalation and expansion trial to evaluate safety, determine the recommended Phase 2 dose (RP2D), and assess antitumor activity in advanced ALK-rearranged tumors. The Phase 2 segment of the trial utilizes objective response rate (ORR) as the primary efficacy endpoint, with secondary endpoints including duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate. While the publicly available results indicate "positive topline pivotal data," the detailed numerical outcomes for ORR, PFS, OS, hazard ratios, confidence intervals, or p-values necessary for a comprehensive statistical analysis are not disclosed. The regulatory designation profile for neladalkib is notably favorable for this indication. Public sources confirm that the drug has received Breakthrough Therapy and Orphan Drug status for previously treated ALK-positive NSCLC, and the FDA has granted Priority Review for the NDA. However, Fast Track designation is not supported by the search results, and there is no indication that Accelerated Approval has been granted. From a commercial perspective, the market for ALK-positive NSCLC remains substantial, with an estimated size of $10-15 billion globally by the mid-2020s. Despite the presence of six approved ALK TKIs, significant unmet needs persist due to acquired resistance mutations and CNS metastases, which continue to limit the durability of treatment benefits across the class. On balance, neladalkib is positioned as a best-in-class program rather than a first-in-class or me-too asset, as it shares the ALK inhibitor mechanism with existing agents but is differentiated by its selectivity, brain penetration, and design intent to maintain efficacy against resistant ALK mutations. The estimated probability of approval (PoA) for neladalkib stands at 85.0%. This figure reflects a late-stage, de-risked program bolstered by FDA filing acceptance, priority review, and positive pivotal topline data. However, the typical risks associated with a crowded therapeutic class remain, necessitating a compelling efficacy and safety profile for approval. Historical precedents in the ALK NSCLC space indicate that FDA decisions are influenced by factors such as response durability, CNS activity, and tolerability compared to existing ALK inhibitors. Programs in this area have generally received approval when they demonstrate meaningful incremental benefits in refractory disease, while those with weaker differentiation have faced challenges during review. Although Nuvalent's track record as a clinical-stage oncology sponsor is relatively limited, the program has progressed through a credible development pathway and was subsequently acquired by GSK, which may enhance regulatory and commercial execution capabilities. Key risks to monitor include the efficacy bar risk, safety and label risk, and competition/precedent risk, all of which could impact the approval process and market positioning.... Show more
ALK-altered NSCLC
Drug: neladalkib (NVL-655). Indication: ALK-altered NSCLC. Timeline: 2026-11-27. Neladalkib (NVL-655) for patients with ALK-altered NSCLC is currently under FDA review, with GSK stating a target decision date of 27 November 2026. NVL-655 is one of the programmes GSK is advancing following the Nuvalent acquisition.... Show more
PolyPid Ltd.
D-PLEX 100
D-PLEX 100 is PolyPid’s lead product candidate, a local, prolonged-release doxycycline formulation designed to provide sustained antibacterial activity directly at the surgical incision to prevent surgical site infections (SSIs) after abdominal colorectal surgery. This innovative approach differentiates D-PLEX from standard systemic perioperative antibiotics, as it aims to deliver local prophylaxis for approximately 30 days, effectively addressing the wound environment where the risk of SSI persists post-closure. Public materials and published translational work highlight the antimicrobial activity of D-PLEX 100 against common SSI pathogens, including both susceptible and resistant organisms. Currently, the program is in the NDA/PDUFA stage, transitioning from active development. The key efficacy dataset is derived from the Phase 3 SHIELD II trial, which involved 798 patients undergoing abdominal colorectal surgery with large incisions. PolyPid reported a positive top-line result, demonstrating statistically significant reductions across both the primary and key secondary endpoints. The primary efficacy endpoint was met with a p-value of less than 0.005, while the first key secondary endpoint revealed a 58% reduction in SSI rates, decreasing from 9.5% with standard care to 3.8% with D-PLEX 100 combined with standard care. A subsequent company presentation indicated a 60% reduction in SSI rates with a p-value of 0.0013. Earlier Phase 2 data from elective colorectal surgery showed an SSI rate of 8% for D-PLEX compared to 22% for standard care, with a p-value of 0.0115. Although the earlier SHIELD 1 trial did not meet its primary outcome, exploratory analyses suggested potential benefits in higher-risk subgroups. Safety data thus far appear reassuring. In the Phase 2 trial, there was no statistically significant difference in treatment-emergent adverse events, serious adverse events, or any TEAEs deemed related to the study drug. The SHIELD 1 trial also reported a favorable safety profile, with no differences in treatment-emergent adverse events. No major signals of local toxicity have emerged from the publicly available data. Regarding regulatory designations, D-PLEX 100 has received Fast Track and Breakthrough Therapy designations for this indication, and the NDA has been granted Priority Review. There is no indication of Orphan Drug or Accelerated Approval status for this indication, as the condition is not classified as rare. The market analysis indicates a global market size of approximately $2.5 billion for colorectal and abdominal surgical site infection prevention and related perioperative SSI prophylaxis spend. Despite the availability of standard perioperative antibiotics and prevention bundles, there remains a significant unmet need, as SSI rates after colorectal surgery are clinically meaningful. D-PLEX 100 addresses this gap by targeting local, sustained prophylaxis at the incision site, where systemic antibiotics are less effective. As a first-in-class product, D-PLEX 100 leverages a local prolonged-release antibiotic delivery platform, distinguishing it from existing systemic antibiotic prophylaxis. While the competitive landscape is favorable, it is not devoid of challenges. The standard of care remains systemic antibiotic prophylaxis combined with SSI prevention bundles, highlighting the ongoing unmet need due to the prevalence and cost of colorectal SSIs. Based on the positive Phase 3 data, advanced regulatory status, and significant unmet need, I estimate a probability of approval (PoA) of 72.0%. However, key risks include potential FDA scrutiny regarding the robustness of the evidence base, manufacturing considerations, and any limitations in labeling that may affect broader surgical applications. Upcoming catalysts include the FDA PDUFA action date set for November 28, 2026, alongside potential U.S. commercial launch decisions and EU regulatory filing progress, although specific timelines for these events have not been disclosed.... Show more
prevention of surgical site infections in patients undergoing abdominal colorectal surgery
Drug: D-PLEX 100. Indication: prevention of surgical site infections in patients undergoing abdominal colorectal surgery. Timeline: November 28, 2026. The FDA accepted PolyPid's NDA for D-PLEX 100 with Priority Review for prevention of surgical site infections in abdominal colorectal surgery and set a PDUFA target action date of November 28, 2026; FDA identified no filing review issues.... Show more
Capricor Therapeutics, Inc.
Deramiocel (CAP-1002)
Deramiocel (CAP-1002) is an innovative allogeneic cardiosphere-derived cell therapy developed by Capricor Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). This therapy is specifically designed to slow functional decline and preserve upper-limb ability in patients experiencing progressive disease. Currently, the program is in Phase 3, focusing on the HOPE-3 trial (NCT05126758), which is a multicenter, randomized, double-blind, placebo-controlled study involving both ambulatory and non-ambulatory DMD patients with impaired skeletal muscle function. Recent public disclosures indicate that the trial successfully met its primary endpoint, which is the assessment of upper-limb function as measured by the Performance of the Upper Limb 2.0 (PUL 2.0). Additionally, the trial achieved significant results in key hierarchy-controlled secondary endpoints, reporting a statistically significant slowing of upper-limb disease progression with a p-value of 0.029. Supportive external-comparator data further demonstrated that treated patients experienced a decline of 3.46 PUL 2.0 points over three years, compared to 7.19 points in the comparator group (p=0.019). Safety profiles have been reported as favorable, with no new safety signals identified and no major discontinuation concerns highlighted in public materials. In terms of regulatory status, deramiocel has received Orphan Drug Designation for DMD. However, public sources indicate that it does not qualify for Fast Track or Breakthrough Therapy designations for this specific upper-limb indication. The program has been granted Priority Review for its Biologics License Application (BLA), while the Accelerated Approval pathway is not being pursued. This distinction is crucial, as the current review is based on a conventional approval package that includes a pivotal randomized study rather than relying on a surrogate endpoint. The unmet need for effective therapies in DMD is significant. While advancements in care have been made, upper-limb impairment remains a progressive and clinically relevant issue, particularly as patients lose ambulation and increasingly depend on arm and hand function for daily activities. Deramiocel is classified as first-in-class, as there are currently no approved therapies that utilize its unique cell-therapy mechanism for addressing upper-limb function in DMD. Competitive pressure in the DMD landscape is moderate but not directly comparable. Existing approved DMD therapies are primarily mutation-specific or broadly disease-modifying, while deramiocel differentiates itself by focusing on the preservation of functional capabilities rather than correcting specific genotypes. The primary concern is not the presence of competing therapies within the same mechanistic class, but rather whether the evidence package supporting deramiocel is robust enough to instill FDA confidence in its benefit-risk profile. A relevant precedent can be drawn from the FDA's decision on Elevidys, which highlighted the agency's balancing act between unmet medical need, biomarker and functional data, and evidentiary uncertainty. Other examples include exon-skipping therapies such as casimersen and golodirsen, which demonstrated the FDA's willingness to approve DMD treatments based on limited yet biologically compelling data when the development package and regulatory strategy were well aligned. However, it is important to note that cell therapy programs in rare neuromuscular diseases face heightened scrutiny regarding chemistry, manufacturing, and controls (CMC) and reproducibility compared to small molecule therapies. Overall, the estimated probability of approval (PoA) for deramiocel stands at 62.0%. This figure reflects a favorable outlook for a late-stage rare disease program, bolstered by positive results from the HOPE-3 trial, a high unmet need in the indication, and the acquisition of priority review status. Nevertheless, the probability is not absolute, as the FDA has requested additional data, and there remain significant risks associated with durability, dataset size, and manufacturing expectations. Key risks include potential FDA concerns regarding the durability and interpretability of efficacy data, as the application relies heavily on HOPE-3 results combined with external comparator and extension data rather than a large, long-duration replicated dataset. Additionally, the program has previously faced regulatory scrutiny, including advisory committee discussions and a PDUFA extension, which heightens execution and approvability risks despite a positive top-line trial signal. Furthermore, challenges related to cell-therapy manufacturing, consistency, and CMC expectations continue to pose meaningful risks for both approval and post-marketing commitments. Upcoming catalysts include FDA action on the BLA for deramiocel, with the current target date extended to November 22, 2026, as well as additional FDA correspondence or label discussions related to the amended BLA review, although the timing of these discussions remains undisclosed.... Show more
Duchenne muscular dystrophy (DMD)
Drug: Deramiocel (CAP-1002). Indication: Duchenne muscular dystrophy (DMD). Timeline: 2026-11-22. FDA extended the PDUFA target action date for Capricor's BLA for Deramiocel (CAP-1002) in Duchenne muscular dystrophy to November 22, 2026 after accepting a major amendment containing 24-month HOPE-3 open-label data and additional robustness analyses supporting a refined upper-limb indication.... Show more
Summit Therapeutics Inc.
ivonescimab (SMT112/AK112)
Ivonescimab (SMT112/AK112) is an investigational bispecific antibody developed by Summit Therapeutics, targeting PD-1 and VEGF to integrate immune checkpoint inhibition with anti-angiogenic activity. This drug is specifically indicated for patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a third-generation EGFR TKI. Currently, the program has advanced to the U.S. New Drug Application (NDA)/Biologics License Application (BLA) stage, having submitted its BLA in January 2026. The FDA has accepted this application for filing and assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 14, 2026. The pivotal evidence for ivonescimab comes from the HARMONi trial, a multiregional, randomized, double-blinded, placebo-controlled phase III study. This trial compared ivonescimab combined with platinum-doublet chemotherapy against a placebo plus platinum-doublet chemotherapy in patients with EGFR-mutated NSCLC who had previously progressed on a third-generation EGFR TKI. The study design and patient population align closely with the intended label for ivonescimab. Summit Therapeutics reported that HARMONi met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a hazard ratio of 0.52 (95% CI 0.41-0.66, p<0.00001). However, details regarding overall survival and objective response rates remain less complete in the available sources. Safety profiles have been characterized as manageable, with no new safety signals reported, although the combination of chemotherapy raises concerns about potential hematologic toxicity, infusion reactions, and immune-related adverse events. The market for this indication is notably underserved. After the failure of osimertinib or other third-generation EGFR TKIs, patients typically receive platinum-based chemotherapy, which often yields limited benefits due to complex resistance biology. This scenario underscores a significant unmet need. Ivonescimab is classified as first-in-class, as it uniquely combines PD-1 and VEGF blockade in a single bispecific antibody for this indication, distinguishing it from existing therapies. While the program must contend with established chemotherapy standards and a competitive pipeline of post-osimertinib strategies, its robust randomized phase III PFS results and the relevant trial population represent considerable advantages. Key risks associated with the approval of ivonescimab include the FDA's potential concerns regarding the strength of the data, particularly in relation to overall survival and safety in a highly competitive post-TKI environment. The regulatory landscape is further complicated by the fact that approval is based on a single global phase III dataset, with limited precedents in this specific setting. Although the program has received Fast Track designation for this post-EGFR TKI NSCLC indication, it lacks Orphan Drug, Breakthrough Therapy, Priority Review, or Accelerated Approval designations. Upcoming catalysts include the FDA's PDUFA action date on November 14, 2026, and potential regulatory decisions in China or other regional label expansions, although specific timelines for these events have not been disclosed. The estimated probability of approval (PoA) stands at 62.0%, reflecting a greater-than-even chance of success, albeit not a guarantee. The FDA's evaluation will likely focus on whether PFS data alone is sufficient, the robustness of overall survival and safety data, and the comparative benefit against existing salvage therapies.... Show more
EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer previously treated with a third-generation EGFR TKI
Drug: ivonescimab (SMT112/AK112). Indication: EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer previously treated with a third-generation EGFR TKI. Timeline: 2026-11-14. Summit’s BLA for ivonescimab, based on the global Phase III HARMONi trial in EGFR-mutated, locally advanced or metastatic non-squamous NSCLC after third-generation EGFR TKI, has a PDUFA goal action date of November 14, 2026.... Show more
Vertex Pharmaceuticals Incorporated
povetacicept
Povetacicept is Vertex’s investigational engineered fusion protein designed to inhibit both BAFF and APRIL, two critical cytokines involved in the survival and maturation of B-cells, which play a significant role in the pathobiology of IgA nephropathy (IgAN). This program is specifically targeting adults with IgAN and is currently at the Biologics License Application (BLA) stage, with the FDA having accepted the submission and set a target action date of November 30, 2026. Vertex is pursuing accelerated approval based on promising interim data from the ongoing Phase 3 RAINIER study. Additionally, the earlier RUBY-3 Phase 1/2 open-label study evaluated multiple dose levels in adults with IgAN and other autoimmune kidney diseases, while the later Phase 3 RAINIER study is randomized, double-blind, placebo-controlled, and currently not recruiting. The market for IgAN therapies is substantial, estimated at $15 billion globally, with a clear unmet need. Despite the availability of supportive care and newer agents, adults with IgAN continue to face significant risks of progressive chronic kidney disease (CKD) and end-stage renal disease (ESRD). There remains a pressing demand for a disease-modifying therapy that can provide durable reductions in proteinuria and preserve renal function. Povetacicept is classified as a first-in-class therapy, representing a novel approach to treating IgAN through dual inhibition of BAFF and APRIL. The interim efficacy data from the RUBY-3 study is promising. Patients receiving 80 mg of povetacicept demonstrated a 64% mean reduction in 24-hour urinary protein-to-creatinine ratio (UPCR) at week 48, decreasing from 1.3 g/g to 0.5 g/g, with 65% of patients achieving UPCR levels below 0.5 g/g while maintaining stable estimated glomerular filtration rates (eGFR). Vertex has also reported positive interim results from the Phase 3 RAINIER study, although detailed numerical data from this analysis is not publicly available. Safety profiles appear favorable, with the treatment being well tolerated; however, the open-label design of the RUBY-3 study introduces some uncertainty compared to randomized controlled trials. From a regulatory perspective, povetacicept has received Breakthrough Therapy Designation for IgAN, which underscores its potential significance in addressing this condition. While the BLA is under review for accelerated approval, the confirmation of Priority Review status is not explicitly detailed in available sources, and neither Fast Track nor Orphan Drug designations for this indication are verified. Consequently, while the probability of approval is elevated, it is not guaranteed. The primary advantages of povetacicept include its novel mechanism of action, a robust rationale based on biomarkers and renal risk, and supportive interim efficacy data. Conversely, the main risk lies in the FDA's assessment of whether proteinuria reduction is convincingly linked to long-term kidney benefits. The competitive landscape for IgAN therapies is active, with existing approved treatments and several pipeline agents targeting BAFF/APRIL biology. Vertex must demonstrate not only efficacy but also differentiation in terms of magnitude, durability, and tolerability compared to these competitors. The company has a strong track record in commercialization and regulatory affairs within rare and specialty diseases, which mitigates execution risk. There is no evident history of FDA rejection for this program, and the current review status indicates that the agency has accepted the BLA. Historical precedents in IgAN and renal disease suggest that FDA decisions will depend on the convincing nature of surrogate endpoints, the safety profile for chronic use, and the credibility of confirmatory evidence supporting accelerated approval. Overall, povetacicept presents as a high-quality late-stage asset with a meaningful probability of approval at 78.0%, though it is not without risks as it approaches the final regulatory evidentiary threshold.... Show more
adults with IgA nephropathy (IgAN)
Drug: povetacicept. Indication: adults with IgA nephropathy (IgAN). Timeline: November 30, 2026. The U.S. FDA accepted the BLA submission for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026.
Regeneron Pharmaceuticals, Inc.
cemdisiran (C5 RNAi therapy)
Cemdisiran is Regeneron’s innovative subcutaneously administered siRNA therapy designed to reduce complement factor 5 (C5) levels, aiming to suppress terminal complement activation in patients with anti-AChR-positive generalized myasthenia gravis (gMG). The drug has progressed to the PDUFA stage, indicating an ongoing FDA review of its New Drug Application (NDA) for adults diagnosed with gMG. The pivotal evidence supporting this application is derived from the phase 3 NIMBLE study (NCT05070858), a randomized, double-blind, placebo-controlled trial that enrolled approximately 190 adults across 86 centers in 13 countries over a 24-week period. This trial evaluated the efficacy of cemdisiran monotherapy, cemdisiran in combination with pozelimab, and placebo, focusing on clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the Quantitative Myasthenia Gravis (QMG) scale, and other patient-centered outcomes. Results demonstrated that cemdisiran monotherapy significantly outperformed placebo on the primary endpoint, achieving a placebo-adjusted MG-ADL improvement of approximately -2.30 at week 24, with a statistically significant p-value. Secondary endpoints also favored the monotherapy, with a higher proportion of patients experiencing a ≥3-point MG-ADL response. Safety profiles appeared manageable, with treatment-emergent adverse events being common but consistent with expectations for this therapeutic class, and no major new safety signals reported. In terms of regulatory designations, the landscape for gMG is somewhat mixed. While the combination of pozelimab and cemdisiran has received FDA orphan designation for myasthenia gravis, the designation for cemdisiran monotherapy does not exhibit the strength of a breakthrough therapy profile. No public evidence indicates that cemdisiran has received Fast Track, Breakthrough Therapy, Priority Review, or Accelerated Approval specifically for gMG. Nonetheless, the robust phase 3 data and the advanced stage of the regulatory filing significantly enhance the drug's approval prospects. From a commercial perspective, the gMG market is both attractive and competitive. Existing approved therapies encompass symptomatic treatments, immunosuppressants, FcRn blockers, and complement inhibitors, creating a high bar for differentiation. For cemdisiran, the novel mechanism of action as an RNA interference (RNAi) therapeutic targeting upstream C5 production supports its classification as first-in-class, distinguishing it from me-too or best-in-class therapies. The unmet need in this space remains substantial, as many patients cycle through multiple treatments before achieving stable control, with some remaining refractory to existing options. The estimated probability of approval (PoA) for cemdisiran stands at 88.0%. This figure reflects the positive late-stage phase 3 dataset, the active regulatory review process, and the mechanistic credibility of the product in addressing a clear unmet need within the gMG patient population. However, several risks must be considered. These include potential FDA scrutiny regarding long-term safety, durability, and class-effect infection risks associated with complement inhibition. Additionally, there is a risk of commercial differentiation challenges against established gMG therapies, particularly approved complement inhibitors and FcRn inhibitors. The NDA's reliance on a single pivotal phase 3 package means that any concerns related to chemistry, manufacturing, and controls (CMC), safety, or subgroup analyses could impact the timing of final approval or the breadth of the label. Nevertheless, historical precedents in gMG and complement-mediated diseases suggest that statistically significant and clinically meaningful functional improvements, coupled with an acceptable safety profile, typically support approval, even though label breadth and differentiation may be constrained by the competitive treatment landscape.... Show more
generalized myasthenia gravis (gMG)
Drug: cemdisiran (C5 RNAi therapy). Indication: generalized myasthenia gravis (gMG). Timeline: November 2026. Regeneron's cemdisiran (C5 RNAi therapy) NDA for adult generalized myasthenia gravis was accepted for review; FDA granted priority review with a PDUFA target action date in November 2026 following use of a Priority Review Voucher.... Show more
Teva Pharmaceutical Industries Limited
IGALMI® (dexmedetomidine)
IGALMI® (dexmedetomidine) is a selective α2A-adrenergic receptor agonist formulated as an orally dissolving sublingual film, developed by BioXcel Therapeutics (BTAI). It was approved by the FDA in April 2022 for the acute treatment of agitation associated with bipolar disorders and schizophrenia. This approval positions IGALMI as a first-in-class therapy, being the only sublingual film available for these indications. The drug addresses a significant unmet medical need, as acute agitation in these conditions is a medical emergency requiring immediate management. Current treatment options, such as benzodiazepines and intramuscular antipsychotics, often involve invasive administration and carry substantial adverse effects. IGALMI offers a non-invasive, rapid-acting alternative that could transform the management of acute agitation. Market analysis indicates that while specific market size figures are not explicitly quantified in available sources, the need for effective treatments for acute agitation in bipolar disorder and schizophrenia is critical. The existing therapies are often associated with adverse effects and require invasive administration, underscoring the demand for alternatives like IGALMI that can be administered quickly and effectively. The drug's classification as first-in-class highlights its unique delivery mechanism and pharmacological approach, which differ fundamentally from traditional benzodiazepines and antipsychotics. Currently, IGALMI is approved for its indicated use, with the PDUFA date referenced likely relating to a supplemental NDA for Alzheimer's disease agitation, based on the positive results from the TRANQUILITY II trial. This trial involved two Phase 3 studies, including NCT04276883, which were randomized, placebo-controlled, and double-blinded, enrolling at least 246 patients with a history of agitation despite stable treatment. The primary endpoint focused on the mean change from baseline at 2 hours in the Positive and Negative Syndrome Scale-Excited Component (PEC) total score. Both tested doses of IGALMI (120 μg and 180 μg) demonstrated statistically significant reductions in PEC scores at 2 hours compared to placebo, with the 180 μg dose particularly effective for managing severe agitation. The safety profile of IGALMI indicates that the most common adverse events include mild somnolence, oral paresthesia, dizziness, dry mouth, and hypotension. Importantly, no serious adverse events were reported during clinical trials. However, there are notable safety concerns, including risks of QT interval prolongation, bradycardia, and hypotension, especially in vulnerable populations such as the elderly, diabetic, or hypovolemic patients. Additionally, the drug's safety and efficacy have not been studied beyond 24 hours, raising concerns about potential tolerance, physical dependence, and withdrawal symptoms with prolonged use. IGALMI's mechanism of action and competitive positioning set it apart from existing treatments. As a non-invasive alternative to intramuscular benzodiazepines and antipsychotics, it fulfills a critical need for rapid management of acute agitation. Currently, no direct competitors with a similar mechanism or formulation have been identified in the market. BioXcel Therapeutics has demonstrated regulatory competence by successfully obtaining FDA approval for IGALMI. The company is actively pursuing label expansion into Alzheimer's disease agitation, supported by positive Phase 3 results from the TRANQUILITY II trial. However, the current PDUFA date's indication remains ambiguous, and if it pertains to Alzheimer's disease agitation, the probability of approval (PoA) for this new indication cannot be reliably estimated from the available data. The PoA for IGALMI is estimated at 5-15%, reflecting uncertainty regarding the specific submission being evaluated. Key risks associated with IGALMI include cardiovascular safety concerns, particularly regarding QT prolongation and hemodynamic effects in vulnerable populations, which may limit clinical uptake despite favorable trial safety data. Additionally, the limited duration of use poses challenges for chronic or recurrent agitation scenarios. Upcoming catalysts include the regulatory decision on the supplemental NDA for Alzheimer's disease indication and the accumulation of real-world evidence and post-marketing safety data from the approved bipolar/schizophrenia indication. Overall, IGALMI represents a promising advancement in the treatment of acute agitation, with significant potential to address unmet medical needs in this patient population.... Show more
Acute treatment of agitation associated with bipolar disorders, schizophrenia
The FDA has assigned a PDUFA target action date for the supplemental New Drug Application (sNDA) for IGALMI, marking a potential first treatment option for agitation in the at-home setting.
Cytokinetics, Incorporated
MYQORZO (aficamten)
As of May 13, 2026, MYQORZO (aficamten) has already received FDA approval on December 19, 2025, and is commercially available in the United States as of January 27, 2026. Additionally, it has secured European Commission approval on February 17, 2026. Given this context, a traditional Probability of Approval (PoA) analysis is not applicable; however, a retrospective examination of the approval pathway and current regulatory status is warranted. MYQORZO is currently approved and commercialized, having undergone a pivotal Phase 3 trial known as SEQUOIA-HCM, which was a randomized, placebo-controlled study involving 282 adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) over a 24-week treatment period. The primary endpoint focused on exercise capacity, specifically peak oxygen uptake (pVO₂) measured through cardiopulmonary exercise testing. The results were compelling, with the MYQORZO group demonstrating a statistically significant increase in pVO₂ of 1.76 mL/kg/min from baseline, compared to no change in the placebo group (p=0.000002). Secondary endpoints also showed favorable outcomes, with 59% of MYQORZO patients experiencing improvement in New York Heart Association (NYHA) functional class compared to 24% in the placebo group. The safety profile of MYQORZO, as noted in FDA documentation, indicates a risk of reduced heart muscle contraction potentially leading to heart failure, necessitating careful monitoring. While specific adverse event rates were not detailed, no major safety signals emerged as barriers to approval. The drug is designed for reversibility and predictable exposure-response, suggesting a favorable safety profile. MYQORZO has received several regulatory designations for HCM, including Breakthrough Therapy Designation and Priority Review, reflecting the FDA's recognition of the significant unmet medical need in symptomatic obstructive HCM. Notably, while HCM is classified as a rare disease, it lacks Orphan Drug Designation. The market opportunity for MYQORZO is substantial, with an estimated global market size of $2.5–4.0 billion in 2026. The unmet need is significant, as prior treatment options have been limited to symptomatic management or invasive therapies, with MYQORZO representing the first oral, non-invasive, disease-modifying therapy targeting the underlying hypercontractility of the condition. In terms of competitive positioning, MYQORZO stands out as a first-in-class therapy with a unique mechanism of action as an allosteric, reversible cardiac myosin inhibitor. This mechanism differentiates it from existing treatments, which primarily focus on symptomatic relief. The competitive landscape includes traditional therapies such as beta-blockers and calcium channel blockers, as well as invasive septal reduction therapies. Notably, MYQORZO has succeeded where mavacamten, another myosin inhibitor, failed in the EXPLORER-HCM trial, which has raised regulatory concerns about the class. Cytokinetics, the developer of MYQORZO, has a strong track record in cardiac drug development, having previously secured FDA approval for omecamtiv mecarbil in April 2023. This history enhances confidence in the company's ability to navigate regulatory pathways effectively. While MYQORZO's approval marks a significant milestone, several risks remain. These include the potential for heart failure exacerbation, limited market penetration due to the rarity of HCM, competitive pressures from emerging therapies, reimbursement challenges, and the need for long-term safety data beyond the initial trial period. Upcoming catalysts include long-term follow-up data from SEQUOIA-HCM extension studies and potential label expansions. In conclusion, MYQORZO represents a groundbreaking advancement in the treatment of symptomatic obstructive HCM, addressing a critical unmet need with its novel mechanism and favorable efficacy profile. The drug's approval and commercialization signify a pivotal moment for Cytokinetics, positioning it as a leader in this emerging therapeutic category. The estimated Probability of Approval for MYQORZO stands at 100%, reflecting its successful regulatory journey and market entry.... Show more
obstructive hypertrophic cardiomyopathy (sNDA label update, MAPLE-HCM)
Drug: MYQORZO (aficamten). Indication: hypertrophic cardiomyopathy (HCM). Timeline: 2026-11-14. FDA accepted for filing the supplemental NDA for MAPLE-HCM for MYQORZO (aficamten); FDA set a PDUFA target action date of November 14, 2026.
• FAQs